hec_m_safety

Genzyme has an on-going commitment to help provide access to Hectorol for all patients.

While many patients have a prescription benefit, for those who do not or whose prescription benefit is limited or requires prior authorization, getting prescription drugs may be a challenge. To help these patients, the Genzyme Renassist^SM program offers a variety of value added services that make Hectorol more accessible. Our dedicated team of Renassist Case Managers makes the process easy. They can work with you to determine the type of assistance necessary for each of your patients.

Renassist Case Managers can consult with you by phone or visit you on site and help educate on reimbursement issues. Case Managers act in accordance with patient privacy regulations (HIPAA) to maintain patient confidentiality. These services are offered at no cost to the healthcare professional or patient.

With just one phone call, you can help your patients gain access to Hectorol. Call 1-800-847-0069.

The Renassist and Patient Assistance application form allows your patients to first have their insurance coverage verified and if benefits are unavailable, apply for free drug.

Hectorol Injection Information
The appropriate Hectorol Injection nomenclature for billing is as follows:
J1270 Injection, doxercalciferol - 1 mcg

Contact your Medicare Carrier or intermediary to verify specific local billing procedures. For directions in filling out a UB-92 (CMS 1450) form for reimbursement for Hectorol Injection and justification for iPTH testing click here.

Hectorol is indicated for the treatment of secondary hyperparathyroidism in patients with Stage 3 or Stage 4 chronic kidney disease (capsules) and in patients with chronic kidney disease on dialysis (capsules and injection)∙ Hectorol is contraindicated in patients with a tendency towards hypercalcemia or evidence of vitamin D toxicity ∙ Overdosage of any form of vitamin D is dangerous∙ Acute hypercalcemia may exacerbate tendencies for cardiac arrhythmias and seizures and may potentiate the action of digitalis drugs∙ Chronic hypercalcemia can lead to generalized vascular and soft tissue calcification∙ Pharmacologic doses of vitamin D and its derivatives should be withheld during Hectorol treatment to avoid possible additive effects and hypercalcemia∙ Magnesium-containing antacids and Hectorol should not be administered concomitantly∙ Adverse effects of Hectorol treatment are: hypercalcemia, hyperphosphatemia, hypercalciuria, and oversuppression of iPTH∙ Adverse events reported by ³ 5% of the Hectorol-treated predialysis patients included: infection, chest pain, constipation, dyspepsia, anemia, dehydration, depression, hypertonia, insomnia, paresthesia, increased cough, dyspnea and rhinitis ∙ Adverse events reported by ³ 5% of the Hectorol-treated dialysis patients included: headache, malaise, bradycardia, nausea/vomiting, edema, dizziness, dyspnea, and pruritus. See Hectorol Capsules Full Prescribing Information or Hectorol Injection Full Prescribing Information.


	Terms and Conditions of Use \| Privacy Policy \| ©	2008 Genzyme Corporation. All rights reserved.